Since its creation in 2003, ECPC has established a series of partnerships with fundamental stakeholders in order to maximise the impact of ECPC activities.

The mission of the Cancer Drug Development Forum (CDDF) is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, the pharmaceutical industry and patient advocates) to improve the efficiency of cancer drug development. CDDF greatly contributed to the development of one of ECPC’s most important projects, the Immuno-Oncology Porta, by providing key funding and via the expert opinion of CDDF Chairmain Prof Heinz Zwierzina. 

Image result for European Alliance for Personalised Medicine (EAPM)

The European Alliance for Personalised Medicine (EAPM) brings together professional and patient advocacy groups with extensive scientific, clinical, caring and training expertise in Personalised Medicine and diagnostics, as well as leading academic institutions, industry and other expert stakeholders. The alliance is co-chaired by former member of the European Parliament, John Bowis and former EU health commissioner David Byrne. The European Cancer Patient Coalition is a founding member of the Alliance and a key partner in the Alliances’ initiatives.

The European Association of Urology (EAU) represents the leading authority within Europe on urological practice, research and education. Its mission is to raise the level of urological care and to facilitate the continued development of urology in Europe and beyond. In 2012, the EAU Patient Information was established with the aim to provide reliable patient information - on a variety of urological diseases - based on the latest scientific evidence, expert recommendations and patient’s needs.

The ECPC and the EAU embarked upon the EAU Patient Information project on Bladder Cancer in 2015. This collaboration is based on patient feedback and is considered an important step in the development of patient information, bringing together two major players responsible for the dissemination of accurate information to cancer patients throughout Europe.


The European Cancer Concord is a unique patient-centered partnership that acts as a catalyst to achieve improved access to an optimal standard of cancer care and research for European citizens. ECPC and ECC collaborated in 2014 to launch the “European Cancer Patient’s Bill of Rights,” a patient charter that will underpin equitable access to an optimal standard of care for Europe’s citizens. 

Image result for ecco european cancer
The European CanCer Oganisation (ECCO) federates some of Europe’s most important professional associations in cancer. ECCO is also in charge of the organisation of the European Cancer Congress. ECPC inputs directly in the design and organisation of the European Cancer Congress Patients’ Track, via the work of ECPC Secretary Jana Pelouchova, who is a member of the ECCO Patient Advisory Committee.


Expert Group on Cancer Control

Initiative on Breast Cancer (ECIBC)

Working Group on mHealth Assessment Guidelines

Joint Actions

Joint Actions are initiatives launched by the European Commission, in partnership with several EU Member States which collaborate on voluntary basis. The objective of the Joint Actions is to increase collaboration between the Member States and progress the level of harmonisation. ECPC is a key partner in all Joint Actions related to cancer, including:

European Health Policy Forum

ECPC is a member of the Health Policy Forum which meets twice a year in Brussels. The overarching goal of the EU Health Forum is to contribute to the development and implementation of actions to protect and improve the health of European citizens.

Image result for european medicines agency
The European Medicines Agency, created in 1995, is the agency of the European Union which evaluates new medicines. EMA authorises the commercialisation of all new cancer drugs.

Kathi Apostolidis and Rafal Swierzewski are the ECPC representatives in EMA’s Patients’ and Consumers’ Working Party of the Committee for Medicinal Products for Human Use (CHMP). Their main task is to extend an intensive cooperation between cancer patients and the European Medicines Agency, so that cancer patients are strongly involved in all possible procedures within EMA (e.g. benefit/risk assessment in Scientific Advise procedures; Package Leaflets assessment; participation in Scientific Advisory Group in case of oncology). Patients’ contribution is very important also for Pharmacovigilance e.g. adverse drug reaction reporting as well as pushing national authorities to implement all rules of the Pharmacovigilance Directive.

The European Organisation for the Research and Treatment of Cancer (EORTC) is one of the most important academic research institutions in Europe in the field of cancer. The ultimate goal of the EORTC is to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery and/or radiotherapy that are already in use. ECPC and EORTC collaborate on several topics on common interest, ranging from policy issues related to cancer to patients’ awareness and empowerment. In 2016, ECPC and EORTC jointly organised second edition of the Cancer Clinical research methodology Course for Patient Advocates.

Image result for esmo logo

Founded in 1975, the European Society for Medical Oncology (ESMO) is one of the leading European professional organization for medical oncology. It comprises more than 13.000 oncology professionals from 130 countries and it represents a reference point for education and information in the field of oncology. ECPC and ESMO have a long standing history of collaboration. ECPC is represented within the ESMO Patient Advocates Working Group, which is responsible for the optimisation of patient care in Europe and worldwide, the continuous improvement of cancer-specific information and education, the strengthening of patient autonomy and the support of patient rights.

 Image result for oeci

ECPC has established a cooperation with the OECI since 2013. Both organisations are interested in finding solutions in order to reduce inequalities in cancer care among Member States. Both Organisations also cooperate in EU research projects. ECPC was glad to have been consulted about the new OECI standards of quality care and designation system and labels. In September 2015 ECPC and OECI signed an official Memorandum of Understanding to seize the longstanding collaboration. 

 logoTNC 1


ECPC and TNC signed an official Memorandum of Understanding in May 2019 in Brussels. TNC aims at increasing the engagement of all the relevant stakeholders to improve knowledge and find solutions to the medical and social problems related to toxic neuropathies. TNC as a Special Interest Group was created at the 2018 Peripheral Nerve Society (PNS) meeting in Baltimore. The PNS is an international organization of physicians and scientists working together to develop and provide the best treatments for people who have peripheral nerve diseases. 

The Union for International Cancer Control (UICC) is a membership organisation that exists to help the global health community accelerate the fight against cancer. Founded in 1933 and based in Geneva, UICC’s growing membership of over 900 organisations across 155 countries, features the world’s major cancer societies, ministries of health, research institutes and patient groups. Together with its members, key partners, the World Health Organization, World Economic Forum and others, UICC is tackling the growing cancer crisis on a global scale. Following a series of meetings between ECPC and UICC leaderships, ECPC was invited to become a UICC Member. Since 2015 ECPC is a Full Member of the Union and kept close ties with the leadership to identify future areas of collaborations between ECPC and UICC in Europe and beyond. 

 WIN logo 2

ECPC is one of 43 institutional members of the Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine. Established in 2010, WIN is a non-profit, non-governmental organization aiming to improve patient outcomes worldwide by increasing the number of patients accessing innovative, global clinical trials in the area of genomic-based cancer therapeutics. WIN develops and applies promising advances in genomic-based cancer research through worldwide clinical trials and research projects, rapidly translating personalized cancer medicine discoveries into standards of patient care worldwide.